Patents Examined by Prema Mertz
  • MPHOSPH1 peptides and vaccines including the same
    Patent number: 9458447
    Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: October 4, 2016
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
  • Anti-IL-33 antibodies
    Patent number: 9453072
    Abstract: The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 27, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
  • Antagonists of interleukin-2 receptor
    Patent number: 9428567
    Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: August 30, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Kenan Christopher Garcia, Aron Levin, Aaron Ring
  • Method of treating Crohn's disease by administering an anti-IL-12 antibody
    Patent number: 9428579
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: August 30, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Method for treating psoriasis by administering an anti-IL-12 antibody
    Patent number: 9409984
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: August 9, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Fibromodulin peptide
    Patent number: 9409963
    Abstract: Embodiments of the present invention provide a fibromodulin (FMOD) peptide (FMOD-P), a composition and a formulation comprising a FMOD-P, option-ally with a TGF-? isoform, or comprising FMOD with a TGF-? isoform. The present invention also provides methods of making and using the FMOD-P, composition, or formulation.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: August 9, 2016
    Assignee: The Regents of the University of California
    Inventors: B. Chia Soo, Kang Ting, Zhong Zheng
  • Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
    Patent number: 9403906
    Abstract: The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumor, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: August 2, 2016
    Assignee: Cantargia AB
    Inventors: Thoas Fioretos, Marcus Jaras
  • Antibody to human IL-1 beta
    Patent number: 9404930
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 2, 2016
    Assignee: DELENEX THERAPEUTICS AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schäfer
  • HJURP peptides and vaccines including the same
    Patent number: 9403890
    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 2, 2016
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Compositions of A-8R peptide
    Patent number: 9393254
    Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: July 19, 2016
    Assignee: The University of Toledo
    Inventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
  • Antibody to human IL-3 receptor alpha chain
    Patent number: 9394370
    Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 19, 2016
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
  • Methods to produce mast cell culture
    Patent number: 9394519
    Abstract: The present invention relates to mast cell cultures that are derived from hematopoietic progenitors and the use thereof. The invention describes a method for generating in-vitro cultures of human mast cells with functional phenotype of connective tissue-type mast cells. By monitoring the levels of chemokines released into the medium, such mast cell cultures can be used as a cell-based assay to assess regulation of mast cell functions and pharmacological activities of tryptase inhibitors.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: July 19, 2016
    Assignee: Apollonian Biosystems Limited
    Inventors: See-Ying Tam, Yee San Issan Tam, Hang Yung Alaster Lau
  • Methods of using biomarkers for predicting the outcome of an immunotherapy against cancer
    Patent number: 9389235
    Abstract: The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: July 12, 2016
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Harpreet Singh, Andrea Mahr, Jens Fritsche
  • Method of treating pulmonary disease by administering an antibody to G-CSF
    Patent number: 9376682
    Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: June 28, 2016
    Assignee: CSL LIMITED
    Inventors: David Eric Crump, Andrew Donald Nash
  • Controlling Pseudomonas aeruginosa persister cells with GM-CSF
    Patent number: 9370189
    Abstract: The present invention relates to host immune factors and antibiotics and, more particularly, to a system and method for controlling and reducing the antibiotic tolerance of bacterial persister cells with host immune factors.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 21, 2016
    Assignee: Syracuse University
    Inventors: Dacheng Ren, Geetika S Choudhary, Xiangyu Yao
  • Interleukin-10 fusion proteins
    Patent number: 9346872
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: May 24, 2016
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Method of treating type 1 diabetes with antagonist IL-7 receptor antibodies
    Patent number: 9346885
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 24, 2016
    Assignee: Rinat Neuroscience Corp.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: 9340613
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 17, 2016
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Method of reducing recurrence of multiple sclerosis symptoms in a mammal by administering an anti-repulsive guidance molecule neutralizing antibody
    Patent number: 9334323
    Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: May 10, 2016
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Toshihide Yamashita, Takekazu Kubo
  • Multimeric IL-15 soluble fusion molecules and methods of using same
    Patent number: 9328159
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: May 3, 2016
    Assignee: Altor Bioscience Corporation
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han